Cancer journal最新文献_第7页

Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches. III 期可切除黑色素瘤的治疗--辅助和新辅助方法。

IF 2.2 4区医学

Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000706

Ahmad A Tarhini, Ella Castellano, Islam Eljilany

{"title":"Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.","authors":"Ahmad A Tarhini, Ella Castellano, Islam Eljilany","doi":"10.1097/PPO.0000000000000706","DOIUrl":"10.1097/PPO.0000000000000706","url":null,"abstract":"Abstract: Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti-cytotoxic T-lymphocyte antigen 4 ipilimumab at 10 mg/kg compared with placebo and ipilimumab 3 mg/kg compared with high-dose interferon α. In the modern era, more recent phase III trials demonstrated significant recurrence-free survival improvements with anti-programmed cell death protein 1, pembrolizumab, and BRAF-MEK inhibitor combination dabrafenib-trametinib (for BRAF mutant melanoma) versus placebo. Furthermore, anti-programmed cell death protein 1, nivolumab and pembrolizumab have both been shown to significantly improve recurrence-free survival as compared with ipilimumab 10 mg/kg. For melanoma patients with clinically or radiologically detectable locoregionally advanced disease, emerging data support an important role for preoperative systemic neoadjuvant therapy. Importantly, a recent cooperative group trial (S1801) reported superior event-free survival rates with neoadjuvant versus adjuvant therapy. Collectively, current data from neoadjuvant immunotherapy and targeted therapy trials support a future change in clinical practice in favor of neoadjuvant therapy for eligible melanoma patients.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 2","pages":"54-70"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma? 转移性黑色素瘤靶向治疗的时机和作用是什么？

IF 2.2 4区医学

Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000712

Matthew J Hadfield, Ryan J Sullivan

{"title":"What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?","authors":"Matthew J Hadfield, Ryan J Sullivan","doi":"10.1097/PPO.0000000000000712","DOIUrl":"10.1097/PPO.0000000000000712","url":null,"abstract":"Abstract: Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with melanoma harbor activating mutations in the BRAF proto-oncogene, a key component of the mitogen-activated protein kinase (MAPK) intracellular signaling pathway. Therapies targeting BRAF have led to remarkable improvements in both response rates and survival in patients with metastatic disease. In parallel with these developments in MAPK-targeted therapy has been the clinical development of immune checkpoint inhibitors, which also have improved response rates and survival in patients with metastatic disease including randomized trials compared with MAPK-targeted therapy in patients with advanced, BRAF-mutant melanoma. Immune checkpoint inhibitors have become the preferred first-line standard-of-care treatment for patients with newly diagnosed metastatic disease in patients irrespective of BRAF mutational status. Given these developments, it is now less clear how to optimize the use of MAPK-targeted therapy regarding treatment setting and in sequence with immune checkpoint inhibitor.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 2","pages":"84-91"},"PeriodicalIF":2.2,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma. 转移性黑色素瘤瘤内注射疗法的作用和现状

IF 2.2 4区医学

Cancer journal Pub Date : 2024-03-01 DOI: 10.1097/PPO.0000000000000709

Alexandra M Haugh, Adil I Daud

引用次数: 0

Telehealth and Outcomes in Patients With Cancer: Data and Innovation. 远程医疗与癌症患者的治疗效果：数据与创新。

IF 2.2 4区医学

Cancer journal Pub Date : 2024-01-01 DOI: 10.1097/PPO.0000000000000697

Michael J Grant, Ann C Chiang

引用次数: 0

Telehealth in Cancer Care: Inequities, Barriers, and Opportunities. 癌症护理中的远程保健：不平等、障碍和机遇。

IF 2.6 4区医学

Cancer journal Pub Date : 2024-01-01 DOI: 10.1097/PPO.0000000000000694

Ana Maria Lopez

{"title":"Telehealth in Cancer Care: Inequities, Barriers, and Opportunities.","authors":"Ana Maria Lopez","doi":"10.1097/PPO.0000000000000694","DOIUrl":"10.1097/PPO.0000000000000694","url":null,"abstract":"Abstract: Telecommunications technology began to be integrated into health care delivery by the mid-1900s, with the goal of increasing access to care including access to cancer care.There have been at least 3 significant telehealth expansion periods, with the most recent related to the COVID-19 pandemic. Technology uptake increased in the 1990s as quality improved, costs came down, and usability factors were addressed. As telehealth practice transitioned to use of personal devices, the COVID-19 pandemic arose, and necessity compelled widespread telehealth uptake. Most patients and clinicians entered the pandemic with little if any telehealth experience and often no training on using personal devices to access health care. Teleoncology data reveal cancer care feasibility and acceptability with generally high levels of satisfaction for both patients and clinicians. Sustaining the progress made in telehealth uptake requires ongoing insurance coverage with parity in coverage, licensure facilitation, and ongoing development of technology that is easy to use. In addition, to tele-cancer care appointments, the technology may be used for care coordination, education, and increased access to cancer clinical trials.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"30 1","pages":"2-7"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital Health for Oncological Care. 肿瘤护理的数字健康。

IF 2.2 4区医学

Cancer journal Pub Date : 2024-01-01 DOI: 10.1097/PPO.0000000000000693

Adam B Cohen, Lee H Schwamm

引用次数: 0

Telemedicine and Burnout-How Enhancing Operational Support Can Improve Digital Health Tools. 远程医疗与职业倦怠--加强业务支持如何改善数字医疗工具。

IF 2.2 4区医学

Cancer journal Pub Date : 2024-01-01 DOI: 10.1097/PPO.0000000000000698

Debra Patt, Colleen O'Neill

引用次数: 0

Telemedicine and Cancer: Shifting a Paradigm of Care. 远程医疗与癌症：转变医疗模式。